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Fig. 1. A full-thickness biopsy of the terminal ileum shows
features of granulomatous inflammation at the base of the ulcer.
Anatomical diagnosis. M. tuberculosis infection of the
small bowel.
REFERENCES
1. Spechler SJ. Schimmel EM. Gastrointestinal tract bleeding 01 unknown origin. Arch
Intern Med 1982: 142: 236-240.
2. Thompson IN, saJem AA. Hemingway AP. et al. Specialist Investigation of obscure
gastrointestinal bleeding. Gut 1987; 28: 47-51.
3. Glassock FU. Brenner BM. The major gJomerulopathies. In: Wilson JO. Braunwald E.
Isselbacher KJ. et aJ.. eds. Harrison's Principles of Internal Medicine. 12th 00. New
Yor1c McGraw-Hill, 1991: 117Q-11SQ.
4. Bllller HA. Grand RJ. Lactose intolerance. Am Rev Med 1990; 14: 141.
5. Mathews JB, Silerl W. Operations for peptic ulCef" disease and earty postoperative
complications. In: Sleiseng8l" MH, Fontuan JS, eds. Gasuoinrestina/ Disease.
ParhophysK)iogy. Diagnosis, Management. 5th ed. Philadelphia; WB Saunders, 1993:
713-730.
6. Aosenblan SG, Drake S, Fadem S, W6ch A, l.ifschitz MD. Gasuointestinal blood loss
itl patients wfth chronic renal failure. Am J Kidney Di$ 1982; 1: 232-236.
7. Bemersen B. .Johnsen A, Straume B. BorhoI PG. Jenssen TO, Stakkevold PA-
Towards a true prevaleoce of peptic ulcer; the Soneisa gastI'OitttestinaJ disorder
sD.ldy. Gut 1990; 31: 989-992_
8. Musola R. Franzin G, Monl A. Manfrini C. Prevaience of gasuointestinaJ lesions in
urerric pa!ients undergoing dialysis and after renal transplantation.. Gaszroinresr
Endcsc 1904: 30; 343-346_
9. Zuckennan GR, Cornene GL. CIouse RG, Hanel" HA. Uppet" gastn:Jintestinal bleeding
itt patients with chronic renal fallure. Ann Intern Med 1985: 102: 588-592-
10. MatCuard SP, Weinstock.N. Gasuointestinalang~in renal failure. J CIin
Gastroenterol1988; 10: 482-434.
11. Nawab F. MasU!'S P, SlJbtamani R, Ortego TJ, Thompson CH. Angiodysp/asia in
patients with renal insufficiency. Am J Gastmetlterol 1989; 84: 1297-1301.
12. Steger AC, GaUand AB, Hemingway A, er al. Gastrointestinal haemonhage from a
second C3USl! itt patients with colonic angiodysplasia Br J $urg 1987; 74: 726-727.
13. Riners B, Grabensee 8. Heering P. Malignancy under immunosuppressive therapy
including cyclospolitte. TfIIlsplant Proc 1994: 26: 2656-2657.
14. VilardeU J. Oppenheimer F, TeJbot-Wright R. er al. Increased risk of malignant turners
in renal transplant recipients receiving cyclospo<ine. Transplant Proc 1992; 24: 1948.
15. Suzuki S, Tanaka K, Ohsaka Y. et al. Development of de IWI'O malignancies following
renal transplantatiott: a single centre srudy. Transpianr Proc 1994: 26: 938-940.
16. McCabe RE. Diagnosis of pulmonary infections in immunocompromised patients.
Med Clin North Am 1988: 72; 1067-10~.
17. KoseIj M. ButIJtl)vW: J, Malovrh M. Tuberculosis in renaJ eJlogtaft recipients.
Transplant Proc 1992; 24: 1909-1910.
18. Hall CM, Willalll PA, SWanepoel CA. Mycobacterial ittfectiOtt in renaJ transplallt
recipients. Presentatiott at the Annual Research Day. Department of Medicine.
Urtiversity of Cape Towtt. 17 Sep 1992.
19. Novis BH, Bank S, Marils IN_ GastrointesMal and peritoneal luben;ulosls: a study 01
cases at the Groote Schuur Hospital. 1962-1971. S AIr Med J 1973: 47: 385--372-
20. GiIinsky NH, Marb IN, Kottlel'RE. Price SK. Abdominal tuberculosis: a IQ-year
reYiew. S Air MedJ 198:3; 64: 849-857.
21. Homan WP, Grate WR, Oitteett P. A «-year experience WIth tubercub.ts entenx:oli1is.
World J SuTg 19n; 1: 245-250.
22. I<Iirnadi OE. Qrmerod LP. Gastrointestinal tuberculosis: a retrospective review of 109
cases itI a district geoeraI hospital. 0 J Med 1985; 56; 569-578.
23.. Bhansali SK. Abdominal lUbefeuIc:lsls: experience with 300 cases. Am J Gastroenrerof
19n; 61: 324.-337.
24. Weissman 0, Gumaste W, Dave PS, Keh W. Bleeding from a tubereulous gastric
ulcer. Am J Gasrroenteml1990; 85: 742-744.
25. Rais N, Plumber ST. Undre AA,B~SO. Masslve lower ga5tn:ointestittal
haett'lOlThage as a complicatiott 01 intestinal tuberculosis. J Assoc Physicians India
1987; 35: 647--648.
26. Waghrnare 6G, Holay MO. Cas RN, Kher A. Massive rectal bleeding due to colonic
tuberculosis. J Assoc Ptlysicjans India. 1988: 36(6): 392·393.
27. Pozniak AL. Dalton-Clark HJ, Ralphs ON. Colonic tuberculosis presenting as massive
rectal bleeding. Tut:JercJe 19a5; 66: 295-299.
28. Wainsztein N, Roe! J, Morales JC. [Intestinal h8fT1OrrtJage due to tuberculosis in a
patient with a kidney U"&nsplant] [Spanish]. MedidruJ (8 Aires) 1985; 45(6): 663-666.
Accepted 1 May 1996.
SHORT REPORT
An analysis of DTP-
associated reactions by
manufacturer, batch,
vaccinator, series number
and infant weight
J.G.Benade
Objectives. To detennine whether two commonly used
DTP batches manufactured by Rh6ne-Poulenc Rorer were
more reactogenic than two commonly used batches
manufactured by the South African Institute of Medical
Research.
Design. Prospective study.
Setting. Six community clinics.
Patients. Infants routinely scheduled for their first three
DTP immunisations.
Main outcome measures. Local and systemic adverse
reactions following immunisation with DTP.
Results. Local reactions were significantly more
common with both Rh6ne--Poulenc Rarer products.
Conclusion. AJI adverse reaction rates compared
favourably with those reported by the Centers for Disease
Control.
S Atr Med J 1996; 86: 1288-1290.
Because of inadequate surveillance systems in many local
authorities, it is impossible to substantiate a growing
perception that the diphtheria-tetanus-pertussis vaccine,
DTP-Merieux, manufactured by Rh6ne-Poulenc Rorer, is
more reactogenic than DTP manufactured by the South
African Institute for Medical Research (SAIMR). Since this
climate of uncertainty can eventually undermine the
Expanded Programme on Immunisation, the validity of these
perceptions was investigated by a stUdy of the reaction
profiles of four commonly used vaccine batches, suspected
of unacceptable reactogenicity by some local authorities.
Literature
It is well known that whole-cell pertussis--containing vaccine
is more reactogenic than most of the vaccines routinety
used for immunisations.U The reported incidence of
tenderness, erythema, swelling or induration at the injection
site varies from 300 - 700/1 000 DTP doses, USUally occurs
within 48 hours of vaccination and is mostly setf-limited.l -6 A
nodule may occasionally be palpable at the injection site for
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several weeks, but sterile abscesses have been reported
occasionally (6 - 10 x 1ca doses of DTP). Injection site
abscess rates depend mainly on the sterility of vaccination
practices. Rates of adverse events following immunisation
(AEFI) are lowest when the vaccine is administered in the
buttocks,6 while subcutaneous administration at any site is
particularly prone to cause local AEFI.
A variety of mild-to-moderate systemic effects frequently
occur within 3 - 6 hours of DTP administration and can
persist for 1 - 2 days l..3.3-7 but appear to be without sequelae.s
Fever of ~ 40.5°C is rare and hypotonic hyporesponsive
episodes even more so. The role of DTP in exceedingly rare
neurological illnesses, e.g. prolonged convulsions,
encephalopathy or sudden infant death syndrome, remains
unclear.' The frequencies of local reactions and fever are
known to increase with an increasing number of OTP doses,
while mild-to-moderate systemic reactions decrease with an
increasing number of doses. 5.6.9 Substitution of diphtheria-
tetanus (01) vaccine is advisable in cases of moderate-to-
severe AEFI with DTP.
Subjects and methods
Three high-turnover clinics at both the Western Cape
Regional Services Council (WCRSC) and Kraaifontein
Municipality were selected. Infants aged 3, 41/2 and 6
months, routinely scheduled for their first three DTP
immunisations (DTP1, DTP2, DTP3), were prospectively
enrolled from 1 June 1994 to 30 January 1995. All vaccine
was provided by the Department of National Health (Western
Cape). All vaccinations were administered intramuscularly in
the deltoid area (23-gauge needle) and vials were stored and
handled according to World Health Organisation guidelines.7
Informed consent was obtained and contraindications as
defined by the vaccine package inserts were adhered to.
At WCRSC clinics, infants randomly received either DTP-
Meri;,ux batch K5315 or SAIMR batch G03509 and, at
Kraaifontein clinics, DTP-Merieux J5497 or SAIMR F08609.
Methods of randomisation varied slightly between the two
clinic groups in order to minimise clinic disruption. DTP dose
numbers and batches were recorded on clinic cards to
ensure vaccination with the same batch at consecutive
visits. Each sister kept standardised personal immunisation
records. Parents were requested to notify anyone of the
AEFI described to any sister at the clinic where vaccination
was performed. Notifications were evaluated by clinic sisters
according to a standard questionnaire and by direct
observation. The Epi Info 6 statistical programme was used
to analyse data.
Results
Table I summarises adverse events that followed within
48 - 72 hours of immunisation with the four batches, in
comparison with AEFI rates reported by an authoritative
source.! Redness in the 10 - 24 mm range was most prevalent
(> 75% of cases) and the majority of cases had swelling in the
10 - 39 mm range (> 75% of cases). The majority ot palpable
masses were 10 - 24 mm in diameter (> 75% of cases).
In total, significantly more infants experienced local (2.08
< RR =4.16 < 8.34) and systemic (2.38 < RR =6.84 < 19.67)
reactions with batch J5497 than with F08609. Vaccination
with DTP-Merieux K5315 resulted in significantly more local
reactions (1.47 < RR = 5.15 < 18.65) than vaccination with
SAIMR G03509. DTP-Merieux K5315 was no more
react0genic than SAIMR G03509 at any specific WCRSC
clinic. Merieux J5497 only caused significantly more total
reactions than SAIMR F08609 at the largest Kraaifontein
clinic (2.51 < RR = 5.07 < 10.26).
In total, AEFI cases and controls did not differ in terms of
weight at birth, at DTP1 or at OTP2. In an inception cohort
at the Kraaifontein clinics, the incidence of AEFI declined
significantly with subsequent dose numbers of Merieux
J5497 (P < 0.001). The RR for a local AEFI with J5497 (N =
222), compared with F08609 (N = 183), was 4.12 at DTP1
(95% Cl = 1.43; 11.84), 3.10 at DTP2 (95% Cl = 1.04; 9.25)
and 0.93 at DTP3 (95% Cl = 0.13; 6.54).
The incidence 9f fever was excluded from all calculations,
since thermometers were not used uniformly.
Table I. Rate (per 1 000 doses) of adverse events occurring within 48 - 72 hours of DTP vaccination, regardless of dose number
2.9 0
13.4:1: 3.2'
3.2 2.4
5.31 ot
0 0
1.4 0.8
0 0
0 0
0 0
0 0
J5497 K5315
MMWW (N = 629) (N = 1 059)
Local
Redness 330 6.3 1.9
Swelling 400 55.6; 5.7'
Subcutaneous nodule 12.7 4.7
Pain 500
Systemic
Fever> 38°C 500 14.31 01
Drowsiness 330 3.2 0
Fretfulness 500 17.6 1.9
Vomiting 66 3 0
Persistent, inconsolable crying> 3 hrs 10 3.2 0
Collapse 1.3
Convulsions 0.57 1.6 0
Sterile abscesses 6 x 10' 0 0
Fever> 4O.5°C 3
• Adapted from reference 1.
t Subjectively judged by parent.
:l: Sum of nodules, lnduration and masses.
Merieux SAIMR
F08609 G03509
(N = 748) (N = 1 259)
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Discussion
The local and systemic rates of AEFI with all the batches
used in this study compared very favourably with those
reported by the Immunisation Practices Advisory Committee
of the Centers for Disease Control' (as indicated in Table I)
and the International Children's Center in Paris. 11 Even the
most reactogenic batch, DTP-Merieux J5497, was clearly
within acceptable levels and the majority of local reactions
were relatively minor. At the Kraaifontein clinics, AEFI rates
seemed to depend on the broad socio-economic level of the
community served. The Kraaifontein clinic where two
vaccinators were less prone to AEFI than their colleagues,
suggests differences in vaccine administration technique
among vaccinators. Contrary to international experience, the
incidence of local AEFI for DTP-Merieux J5497 decreased
with increasing dose number, thus indicating that the more
reactogenic individuals were at greatest risk of an AEFI at
DTP1.
Conclusions
Our results prove that perceptions of 'unacceptable levels of
AEFI' for the batches used are unfounded and in danger of
compromising the goals of the Expanded Programme on
Immunisation. ll Improved surveillance at all levels to provide
accurate data for rational decision-making, combined with
increased levels of knowledge about what kind of AEFI are
'acceptable', could contribute substantially towards
attainment of high DTP coverage.
The risk of an AEFI with DTP in this study was determined
by the choice of vaccine manufacturer and batch,
vaccinator, dose series number and the broad socio-
economic group of the patient. More comprehensive studies
are required to determine whether a link exists between AEFI
and vaccine efficacy.
I acknowledge the contributions of the Department of
Community Health, University of Stellenbosch, the former
Western Cape Regional Services Council, the Municipality of
Kraaifontein and the Department of Health.
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HISTORY OF MEDICINE
Was Isaac diabetic?
Azila Talit Reisenberger
Isaac was the second of the three biblical patriarchs of
whom Abraham and Jacob are the first and third. His
position in the middle of this lineage may be responsible for
his mediocre image in the eyes of some readers of the Bible,
an image that is reinforced by the sense of his having been
of a somewhat lethargic personality and not noted for the
bursts of actiVity or feats of physical achievement
associated with other famous biblical figures. This, together
with the rest of the biblical account of his life, affords a
tantalising opportunity to speculate on his medical
condition, specifically the possibility that lsaac might have
been diabetic.
Signs and symptoms
Diabetes mellitus and its complications encompass a
multiplicity of signs, symptoms and secondary conditions,
which include a constant need for water, increased appetite,
lethargy and chronic fatigue, visual deficit due to cataracts
or retinopathy, and sexual dysfunction including impotence.
This paper asserts that a sufficient number of these
conditions can be discerned in lsaac to make him a
probable diabetic.
At the age of 40, lsaac married Rebekah (Genesis 25:20).
Thereafter, the couple evidently experienced a long period of
involuntary infertility, for Rebekah did not become pregnant
until 20 years later when she was delivered of her twin sons,
Esau and Jacob. Isaac was now 60 years old (Genesis 25:
26) - or was he? At this point. it may be appropriate to take
a closer look at the question of Isaac's age. The Bible says
that when he was 100 years old. and when 'his eyes were
too dim to see', he called his eldest son Esau to give him his
blessing, for 'behold, I am grown old, I know not the day of
my death' (Genesis 27: 1·2). Given that such a blessing was
normally bestowed when the giver was on his death-bed,
Isaac must have felt very sick indeed, and it seems
reasonable that, having reached a century, Isaac should be
concerned about his mortality and should begin to think
about bestowing his assets. But Isaac went on to live
another 80 biblical years after this event! The Bible says:
'And the days of Isaac were 180 years. And Isaac departed
this life, and died, and was gathered unto his people old and
full of days; and Esau and Jacob his sons buried him'
(Genesis 35: 28-29).
During the period after the blessing, Isaac'S sons got
married, had many children, and established themselves as
patriarchs in their own right. Isaac even survived family
tragedies such as the rape of his grand-daughter and a
raging neighbourhood dispute that culminated in mass
murder. Despite his own feelings, Isaac was evidently not
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